Internet Use Among Women With Recurrent Metastatic Breast Cancer
NCT ID: NCT00770055
Last Updated: 2011-01-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
70 participants
INTERVENTIONAL
2001-11-30
2011-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: This clinical trial is studying internet use among women with recurrent metastatic breast cancer.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* To document the proportion of women who use the internet to access treatment and symptom management information and to seek emotional support after diagnosis of metastatic recurrent breast cancer.
* To evaluate the association of treatment stage and effectiveness with internet use.
* To evaluate the association of individual differences in patients' demographics, beliefs, emotional functioning, and social and professional support with internet use.
* To evaluate the association of patients' use of the internet to seek resources with their beliefs, emotional functioning, and relationship functioning.
OUTLINE: Patients undergo assessments consisting of paper and pencil questionnaires at four time points. The timing of these assessments is linked to the patient's treatment course and her presumed need to access internet resources for information on cancer, treatment, symptom management, and emotional support. Patients who discontinue regular care at the Cancer Institute of New Jersey site during the course of the study may complete study assessments through phone interviews conducted by a member of the study team.
Patients undergo a baseline survey prior to deciding on a treatment course for their newly progressive disease. Patients complete the first part of the survey to provide information on demographics, beliefs about cancer, mood states, somatic symptoms, and available resources for cancer information and emotional support. Patients complete the second part of the survey, if they have used the internet previously to obtain information and resources about cancer or if they have received cancer information that someone else located on the internet for them, which inquires about patients' internet use, any internet resources they have received from family members, friends, or other people they know, and their own evaluation of these internet resources. Patients undergo the second study assessment after completion of the first course of treatment and prior to initiating course 2 (i.e., 3 to 4 weeks after initiating treatment). The third study assessment occurs within the first 2 weeks after the medical oncologist's first evaluation of treatment response (i.e., 6-9 weeks after initiating treatment). The fourth assessment occurs after the medical oncologist's second evaluation of the patient's response to treatment, following tumor re-staging.
Patients complete several questionnaires during these assessments to provide information about personal characteristics (demographics, physical and psychological well-being, beliefs about cancer and treatment, optimism), social and healthcare networks (perceived social support, social network composition, beliefs about treatment team), and outcomes (use of non-internet cancer information, use of the internet for cancer resources, use of interactive technologies, communication with treatment team and family, evaluation of internet resources).
The following information is extracted from the patients' medical record: stage and node status at primary diagnosis, previous oncology surgeries, previous adjuvant treatments, current menopausal status, treatment at time of recurrence, disease free interval, site(s) of metastasis, and response to current treatment.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
HEALTH_SERVICES_RESEARCH
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
medical chart review
questionnaire administration
survey administration
psychosocial assessment and care
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis of recurrent breast cancer meeting either of the following criteria:
* Newly diagnosed metastatic disease
* Recently diagnosed as progressive disease after stable metastatic disease for at least 6 months
* Must have received the same treatment for metastatic breast cancer for at least 3 months
* Have received no treatment for progressive disease OR have begun treatment for progressive disease within the past month
* Patient at the Cancer Institute of New Jersey in New Brunswick or Hamilton, New Jersey
* Hormone receptor status not specified
PATIENT CHARACTERISTICS:
* Menopausal status not specified
* Able to speak and write English
* Free of diseases and cognitive impairments that would interfere with comprehension of the survey instruments or ability to provide informed consent
PRIOR CONCURRENT THERAPY:
* See Disease Characteristics
18 Years
75 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
University of Medicine and Dentistry of New Jersey
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Deborah Toppmeyer, MD
Role: PRINCIPAL_INVESTIGATOR
Rutgers Cancer Institute of New Jersey
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School
New Brunswick, New Jersey, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CINJ-000102
Identifier Type: -
Identifier Source: secondary_id
CINJ-IRB-3879
Identifier Type: -
Identifier Source: secondary_id
CDR0000592835
Identifier Type: -
Identifier Source: org_study_id